About us   Contacts   Links   Information in Russian 
Research programms
Journal
Bulletin of the Multinational Center of Quality of Life Research

Bulletin of the Multinational Center of Quality of Life Research





T. I. Ionova, D. A. Fedorenko, T. P. Nikitina, K. A. Kurbatova

Quality of life and symptom profile in patients with imatinib-resistant or imatinib-intolerant chronic myeloid leukemia

Seventy imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia were involved in the study. In more than 30% of patients quality of life was severely or critically impaired.

Patients who were charged with standard doses of imatinib during the first-line treatment experienced better quality of life and less severe symptoms than patients who were treated with high doses of imatinib (600 or 800 mg/day). Patients who were intolerant to imatinib treatment showed lower quality of life as compared to patients who were resistant to imatinib treatment (physical functioning, role physical functioning, pain, general health; p<0,05).

A number of symptoms were more severe in patients who were intolerant to imatinib as compared to patients with imatinib resistance. Patient-reported outcomes contribute to comprehensive assessment of treatment efficacy in patients with chronic myeloid leukemia during disease-modifying treatment.




© Создание сайтов

Последнее обновление (last update): 07-12-2021









Яндекс цитирования